221 related articles for article (PubMed ID: 8676446)
1. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.
Friedman HM; Wang L; Fishman NO; Lambris JD; Eisenberg RJ; Cohen GH; Lubinski J
J Virol; 1996 Jul; 70(7):4253-60. PubMed ID: 8676446
[TBL] [Abstract][Full Text] [Related]
2. Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1.
Friedman HM; Wang L; Pangburn MK; Lambris JD; Lubinski J
J Immunol; 2000 Oct; 165(8):4528-36. PubMed ID: 11035093
[TBL] [Abstract][Full Text] [Related]
3. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.
Awasthi S; Lubinski JM; Friedman HM
Vaccine; 2009 Nov; 27(49):6845-53. PubMed ID: 19761834
[TBL] [Abstract][Full Text] [Related]
4. Glycoprotein C of Herpes Simplex Virus 1 Shields Glycoprotein B from Antibody Neutralization.
Komala Sari T; Gianopulos KA; Nicola AV
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826995
[TBL] [Abstract][Full Text] [Related]
5. Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody.
Hook LM; Lubinski JM; Jiang M; Pangburn MK; Friedman HM
J Virol; 2006 Apr; 80(8):4038-46. PubMed ID: 16571820
[TBL] [Abstract][Full Text] [Related]
6. Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E.
Hook LM; Huang J; Jiang M; Hodinka R; Friedman HM
J Virol; 2008 Jul; 82(14):6935-41. PubMed ID: 18480440
[TBL] [Abstract][Full Text] [Related]
7. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC.
Lubinski J; Wang L; Mastellos D; Sahu A; Lambris JD; Friedman HM
J Exp Med; 1999 Dec; 190(11):1637-46. PubMed ID: 10587354
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus type 1 evades the effects of antibody and complement in vivo.
Lubinski JM; Jiang M; Hook L; Chang Y; Sarver C; Mastellos D; Lambris JD; Cohen GH; Eisenberg RJ; Friedman HM
J Virol; 2002 Sep; 76(18):9232-41. PubMed ID: 12186907
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.
Nemerow GR; Jensen FC; Cooper NR
J Clin Invest; 1982 Nov; 70(5):1081-91. PubMed ID: 6290536
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein C of herpes simplex virus type 1 is essential for the virus to evade antibody-independent complement-mediated virus inactivation and lysis of virus-infected cells.
Hidaka Y; Sakai Y; Toh Y; Mori R
J Gen Virol; 1991 Apr; 72 ( Pt 4)():915-21. PubMed ID: 1849974
[TBL] [Abstract][Full Text] [Related]
11. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection.
Judson KA; Lubinski JM; Jiang M; Chang Y; Eisenberg RJ; Cohen GH; Friedman HM
J Virol; 2003 Dec; 77(23):12639-45. PubMed ID: 14610186
[TBL] [Abstract][Full Text] [Related]
12. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism.
Gerber SI; Belval BJ; Herold BC
Virology; 1995 Dec; 214(1):29-39. PubMed ID: 8525631
[TBL] [Abstract][Full Text] [Related]
13. Immune evasion by herpes simplex virus type 1, strategies for virus survival.
Friedman HM
Trans Am Clin Climatol Assoc; 2003; 114():103-12. PubMed ID: 12813914
[TBL] [Abstract][Full Text] [Related]
14. Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization.
Harris SL; Frank I; Yee A; Cohen GH; Eisenberg RJ; Friedman HM
J Infect Dis; 1990 Aug; 162(2):331-7. PubMed ID: 2165106
[TBL] [Abstract][Full Text] [Related]
15. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway.
Hung SL; Peng C; Kostavasili I; Friedman HM; Lambris JD; Eisenberg RJ; Cohen GH
Virology; 1994 Sep; 203(2):299-312. PubMed ID: 8053154
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b.
Rux AH; Lou H; Lambris JD; Friedman HM; Eisenberg RJ; Cohen GH
Virology; 2002 Mar; 294(2):324-32. PubMed ID: 12009874
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity.
McNearney TA; Odell C; Holers VM; Spear PG; Atkinson JP
J Exp Med; 1987 Nov; 166(5):1525-35. PubMed ID: 2824652
[TBL] [Abstract][Full Text] [Related]
18. Binding of complement component C3b to glycoprotein gC of herpes simplex virus type 1: mapping of gC-binding sites and demonstration of conserved C3b binding in low-passage clinical isolates.
Friedman HM; Glorioso JC; Cohen GH; Hastings JC; Harris SL; Eisenberg RJ
J Virol; 1986 Nov; 60(2):470-5. PubMed ID: 3021981
[TBL] [Abstract][Full Text] [Related]
19. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo.
Lubinski JM; Wang L; Soulika AM; Burger R; Wetsel RA; Colten H; Cohen GH; Eisenberg RJ; Lambris JD; Friedman HM
J Virol; 1998 Oct; 72(10):8257-63. PubMed ID: 9733869
[TBL] [Abstract][Full Text] [Related]
20. Viral interference with antibody and complement.
Lubinski J; Nagashunmugam T; Friedman HM
Semin Cell Dev Biol; 1998 Jun; 9(3):329-37. PubMed ID: 9665870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
